255 related articles for article (PubMed ID: 21497649)
1. The medicinal use of realgar (As₄S₄) and its recent development as an anticancer agent.
Wu J; Shao Y; Liu J; Chen G; Ho PC
J Ethnopharmacol; 2011 Jun; 135(3):595-602. PubMed ID: 21497649
[TBL] [Abstract][Full Text] [Related]
2. [Safety issues of traditional Chinese medical preparations containing arsenic substances: review starting from Niuhuang Jiedu Pian (Wan)].
Zhang L; Gao SH; Zhou CF; Lin RC; Liu CH
Zhongguo Zhong Yao Za Zhi; 2006 Dec; 31(23):2010-3. PubMed ID: 17348199
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute promyelocytic leukemia with arsenic trioxide.
Conrad ME
N Engl J Med; 1999 Apr; 340(13):1043-5. PubMed ID: 10189286
[No Abstract] [Full Text] [Related]
4. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite.
Liu J; Lu Y; Wu Q; Goyer RA; Waalkes MP
J Pharmacol Exp Ther; 2008 Aug; 326(2):363-8. PubMed ID: 18463319
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding.
Wu JZ; Ho PC
Eur J Pharm Sci; 2006 Sep; 29(1):35-44. PubMed ID: 16824739
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Kalmadi SR; Hussein MA
Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883
[TBL] [Abstract][Full Text] [Related]
7. Arsenic: a beneficial therapeutic poison - a historical overview.
Thomas X; Troncy J
Adler Mus Bull; 2009 Jun; 35(1):3-13. PubMed ID: 20052806
[TBL] [Abstract][Full Text] [Related]
8. Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.
Wang X; Zhang X; Xu Z; Wang Z; Yue X; Li H
Biol Pharm Bull; 2013; 36(4):641-8. PubMed ID: 23358330
[TBL] [Abstract][Full Text] [Related]
9. [History of realgar processing].
Zhang JX
Zhong Yao Tong Bao; 1987 Mar; 12(3):55-8. PubMed ID: 2957102
[No Abstract] [Full Text] [Related]
10. How acute promyelocytic leukaemia revived arsenic.
Zhu J; Chen Z; Lallemand-Breitenbach V; de Thé H
Nat Rev Cancer; 2002 Sep; 2(9):705-13. PubMed ID: 12209159
[TBL] [Abstract][Full Text] [Related]
11. Introduction: the history of arsenic trioxide in cancer therapy.
Antman KH
Oncologist; 2001; 6 Suppl 2():1-2. PubMed ID: 11331433
[TBL] [Abstract][Full Text] [Related]
12. Biological extraction of realgar by Acidithiobacillus ferrooxidans and its in vitro and in vivo antitumor activities.
Zhang X; Xie QJ; Wang X; Wang B; Li HY
Pharm Biol; 2010 Jan; 48(1):40-7. PubMed ID: 20645754
[TBL] [Abstract][Full Text] [Related]
13. Expanding the use of arsenic trioxide: leukemias and beyond.
Chen Z; Chen GQ; Shen ZX; Sun GL; Tong JH; Wang ZY; Chen SJ
Semin Hematol; 2002 Apr; 39(2 Suppl 1):22-6. PubMed ID: 12012319
[TBL] [Abstract][Full Text] [Related]
14. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.
List A; Beran M; DiPersio J; Slack J; Vey N; Rosenfeld CS; Greenberg P
Leukemia; 2003 Aug; 17(8):1499-507. PubMed ID: 12886236
[TBL] [Abstract][Full Text] [Related]
15. History of the development of arsenic derivatives in cancer therapy.
Waxman S; Anderson KC
Oncologist; 2001; 6 Suppl 2():3-10. PubMed ID: 11331434
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
17. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide in the management of acute promyelocytic leukaemia.
Mathews V; Chandy M; Srivastava A
Natl Med J India; 2001; 14(4):215-22. PubMed ID: 11547528
[TBL] [Abstract][Full Text] [Related]
19. Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview).
Baláž P; Sedlák J
Toxins (Basel); 2010 Jun; 2(6):1568-81. PubMed ID: 22069650
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
